Raymond James Financial Inc. Makes New $2.43 Million Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Raymond James Financial Inc. bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 84,883 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,432,000.

Several other large investors also recently bought and sold shares of the business. JPMorgan Chase & Co. raised its holdings in Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after buying an additional 175,892 shares during the period. Barclays PLC raised its stake in shares of Collegium Pharmaceutical by 152.2% during the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock valued at $2,899,000 after acquiring an additional 45,291 shares in the last quarter. Sanctuary Advisors LLC grew its position in shares of Collegium Pharmaceutical by 10.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock worth $695,000 after buying an additional 1,731 shares in the last quarter. FMR LLC boosted its stake in shares of Collegium Pharmaceutical by 1,532.2% during the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock valued at $1,459,000 after purchasing an additional 35,439 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of Collegium Pharmaceutical by 399.4% in the 3rd quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company’s stock worth $2,686,000 after acquiring an additional 55,572 shares in the last quarter.

Insider Activity

In other news, EVP Scott Dreyer sold 2,255 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now owns 124,421 shares of the company’s stock, valued at $3,732,630. This represents a 1.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares of the company’s stock, valued at $3,937,839.36. This represents a 18.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,193 shares of company stock worth $3,243,594 over the last three months. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $29.71 on Friday. Collegium Pharmaceutical, Inc. has a 1 year low of $27.28 and a 1 year high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company’s fifty day moving average price is $30.36 and its 200 day moving average price is $32.42. The stock has a market capitalization of $935.45 million, a P/E ratio of 12.81 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. As a group, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

COLL has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Friday, January 10th. Finally, Piper Sandler cut their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.